Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study

BACKGROUND: Golimumab (GLM) has been reported to have lower immunogenicity than do other TNF inhibitors used for treating rheumatoid arthritis (RA). We previously found a prolonged effect of and improvement similar to that associated with infliximab (IFX) after switching to subcutaneous GLM (GLM-SC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakabayashi, Hiroki, Nagao, Nobuto, Inada, Hitoshi, Nishioka, Yosuke, Hasegawa, Masahiro, Nishioka, Kusuki, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363693/
https://www.ncbi.nlm.nih.gov/pubmed/34173221
http://dx.doi.org/10.1007/s40268-021-00355-2

Ejemplares similares

Ejemplares similares